Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its third quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by of 44 cents and increased from 41 cents in the year-ago quarter.
Revenues: Baxter posted sales of $2,558 million, beating the Zacks Consensus Estimate for revenues of $2,545 million. At constant currency (cc), revenues increased 4% on a year-over-year basis.
Key Stats: Hospital products sales increased 3% at cc, while renal products went up 6% from the year-ago quarter.
Major Factors: Hospital Products sales were driven by solid demand for IV solutions, nutritional therapies, pharmacy injectables and IV access administration sets. Renal products sales were driven by peritoneal dialysis products as well as increased demand globally for continuous renal replacement therapies.
Stock Price: Following the earnings release, share price rose 2.48% in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Baxter International Inc. (BAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.
Currently, Baxter International has a Zacks Rank #3 (Hold) but that could change following its third quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
Earnings: Baxter’s adjusted earnings of 56 cents per share beat the Zacks Consensus Estimate by of 44 cents and increased from 41 cents in the year-ago quarter.
Revenues: Baxter posted sales of $2,558 million, beating the Zacks Consensus Estimate for revenues of $2,545 million. At constant currency (cc), revenues increased 4% on a year-over-year basis.
Key Stats: Hospital products sales increased 3% at cc, while renal products went up 6% from the year-ago quarter.
Major Factors: Hospital Products sales were driven by solid demand for IV solutions, nutritional therapies, pharmacy injectables and IV access administration sets. Renal products sales were driven by peritoneal dialysis products as well as increased demand globally for continuous renal replacement therapies.
Stock Price: Following the earnings release, share price rose 2.48% in the pre-market trading session.
Check back later for our full write up on this Baxter International report later!
Confidential from Zacks
Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on BAX - FREE